Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Yoko Tabe, Agostino Tafuri, Kazumasa Sekihara, Haeun Yang & Marina Konopleva. (2017) Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia. Expert Opinion on Therapeutic Targets 21:7, pages 705-714.
Read now
Read now
Azam Roohi & Mohammad Hojjat-Farsangi. (2017) Recent advances in targeting mTOR signaling pathway using small molecule inhibitors. Journal of Drug Targeting 25:3, pages 189-201.
Read now
Read now
Articles from other publishers (20)
Ricky Wai Tak Leung, Xiaosen Jiang, Xueqing Zong, Yanhong Zhang, Xinlin Hu, Yaohua Hu & Jing Qin. (2022) CORN—Condition Orientated Regulatory Networks: bridging conditions to gene networks. Briefings in Bioinformatics 23:6.
Crossref
Crossref
Le Yu, Jessica Wei & Pengda Liu. (2022) Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Seminars in Cancer Biology 85, pages 69-94.
Crossref
Crossref
Annika Belzer, Shaman Bhullar & Jonathan S. Leventhal. (2022) PI3K Inhibitor Eruptions: an Overview of Diagnostic and Management Strategies for the Inpatient Dermatologist. Current Dermatology Reports 11:3, pages 158-167.
Crossref
Crossref
Thomas A. Paterniti, Evan A. Schrader, Aditi Talkad, Kasey Shepp, Jesse Wayson, Alexandra M. Poch & Sarfraz Ahmad. 2021. Overcoming Drug Resistance in Gynecologic Cancers. Overcoming Drug Resistance in Gynecologic Cancers
225
266
.
Aisha A. K. Al-Ashmawy, Khaled M. Elokely, Oscar Perez-Leal, Mario Rico, John Gordon, George Mateo, Abdelsattar M. Omar, Magid Abou-Gharbia & Wayne E. ChildersJr.Jr.. (2020) Discovery and SAR of Novel Disubstituted Quinazolines as Dual PI3Kalpha/mTOR Inhibitors Targeting Breast Cancer. ACS Medicinal Chemistry Letters 11:11, pages 2156-2164.
Crossref
Crossref
Chiara Tarantelli, Antonio Lupia, Anastasios Stathis & Francesco Bertoni. (2020) Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?. International Journal of Molecular Sciences 21:3, pages 1060.
Crossref
Crossref
Shengping Yu, Yang Liu, Zhen Zhang, Jingya Zhang & Guisen Zhao. (2019) Design, synthesis and biological evaluation of novel 2,3-indolinedione derivatives against mantle cell lymphoma. Bioorganic & Medicinal Chemistry 27:15, pages 3319-3327.
Crossref
Crossref
Ruth Eichner, Vanesa Fernández-Sáiz, Bianca-Sabrina Targosz & Florian Bassermann. 2019.
219
297
.
Jennifer R Brown, Mehdi Hamadani, John Hayslip, Ann Janssens, Nina Wagner-Johnston, Oliver Ottmann, Jon Arnason, Hervé Tilly, Michael Millenson, Fritz Offner, Nashat Y Gabrail, Siddhartha Ganguly, Sikander Ailawadhi, Siddha Kasar, Arnon P Kater, Jeanette K Doorduijn, Lei Gao, Joanne J Lager, Bin Wu, Coumaran Egile & Marie José Kersten. (2018) Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. The Lancet Haematology 5:4, pages e170-e180.
Crossref
Crossref
Janice M. Mehnert, Gerald Edelman, Mark Stein, Heather Camisa, Joanne Lager, Jean-François Dedieu, Anne-Frédérique Ghuysen, Jyoti Sharma, Li Liu & Patricia M. LoRusso. (2017) A phase I dose-escalation study of the safety and pharmacokinetics of a tablet formulation of voxtalisib, a phosphoinositide 3-kinase inhibitor, in patients with solid tumors. Investigational New Drugs 36:1, pages 36-44.
Crossref
Crossref
Philippe L. Bédard, Michael A. Davies, Scott Kopetz, Dejan Juric, Geoffrey I. Shapiro, Jason J. Luke, Anna Spreafico, Bin Wu, Christelle Castell, Corinne Gomez, Sylvaine Cartot-Cotton, Florent Mazuir, Michel Dubar, Sandrine Micallef, Brigitte Demers & Keith T. Flaherty. (2018) First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer 124:2, pages 315-324.
Crossref
Crossref
L C Kim, R S Cook & J Chen. (2016) mTORC1 and mTORC2 in cancer and the tumor microenvironment. Oncogene 36:16, pages 2191-2201.
Crossref
Crossref
Farrukh T. Awan, Lia Gore, Lei Gao, Jyoti Sharma, Joanne Lager & Luciano J. Costa. (2016)
Phase Ib trial of the
PI
3K/
mTOR
inhibitor voxtalisib (
SAR
245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B‐cell malignancies
. British Journal of Haematology 175:1, pages 55-65.
Crossref
Crossref
Arati A. Inamdar, Andre Goy, Nehad M. Ayoub, Christen Attia, Lucia Oton, Varun Taruvai, Mark Costales, Yu-Ting Lin, Andrew Pecora & K. Stephen Suh. (2016) Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents. Oncotarget 7:30, pages 48692-48731.
Crossref
Crossref
Oliver E. Bechter, Herlinde Dumez, Jo Costermans, Kevin Punie, Karl Hsu, Jean-François Dedieu, Anne-Frédérique Ghuysen, Elisa Francesconi, Jyoti Sharma, Li Liu & Patrick Schöffski. (2016) Phase I safety and pharmacokinetic dose-escalation study of pilaralisib polymorph E, a phosphoinositide 3-kinase inhibitor in tablet formulation, in patients with solid tumors or lymphoma. Cancer Chemotherapy and Pharmacology 78:1, pages 83-90.
Crossref
Crossref
Paul J. Galardy, Tibor Bedekovics & Michelle L. Hermiston. (2016) Targeting childhood, adolescent and young adult non-Hodgkin lymphoma: therapeutic horizons. British Journal of Haematology 173:4, pages 625-636.
Crossref
Crossref
Sander W. Tas, Chrissta X. Maracle, Emese Balogh & Zoltán Szekanecz. (2015) Targeting of proangiogenic signalling pathways in chronic inflammation. Nature Reviews Rheumatology 12:2, pages 111-122.
Crossref
Crossref
R Thijssen, J ter Burg, G G W van Bochove, M F M de Rooij, A Kuil, M H Jansen, T W Kuijpers, J W Baars, A Virone-Oddos, M Spaargaren, C Egile, M H J van Oers, E Eldering, M J Kersten & A P Kater. (2015) The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells. Leukemia 30:2, pages 337-345.
Crossref
Crossref
Thibault Brotelle & Jacques-Olivier Bay. (2016) La voie de signalisation PI3K-AKT-mTOR : description, développement thérapeutique, résistances, marqueurs prédictifs/pronostiques et applications thérapeutiques en cancérologie. Bulletin du Cancer 103:1, pages 18-29.
Crossref
Crossref
Kimberly Blackwell, Howard Burris, Patricia Gomez, N. Lynn Henry, Steven Isakoff, Frank Campana, Lei Gao, Jason Jiang, Sandrine Mac?Sara M. Tolaney. (2015) Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor. Breast Cancer Research and Treatment 154:2, pages 287-297.
Crossref
Crossref